Endometrial Neoplasms Clinical Trials

Recruiting

Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer

NCT07198074

Conditions: Advanced Endometrial Carcinoma, Endometrial Neoplasms, Female Urogenital Diseases, +11 more
Locations: University of Alabama at Birmingham Cancer Center Birmingham, Alabama, United States

Alaska Women's Cancer Care Anchorage, Alaska, United States

Cancer Center at Saint Joseph's Phoenix, Arizona, United States

Highlands Oncology Group - Fayetteville Fayetteville, Arkansas, United States

View all 242 locations

View Trial Details

Recruiting

Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma

NCT05256225

Conditions: Endometrial Carcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Dedifferentiated Carcinoma, +17 more
Locations: University of Alabama at Birmingham Cancer Center Birmingham, Alabama, United States

Alaska Women's Cancer Care Anchorage, Alaska, United States

Banner University Medical Center - Tucson Tucson, Arizona, United States

University of Arizona Cancer Center-North Campus Tucson, Arizona, United States

View all 409 locations

View Trial Details

Recruiting

Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors

NCT06218914

Conditions: Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +32 more
Locations: Research Site Duarte, California, United States

Research Site Los Angeles, California, United States

Research Site Newport Beach, California, United States

Research Site Jacksonville, Florida, United States

View all 18 locations

View Trial Details

Recruiting

Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer

NCT07022483

Conditions: Endometrial Cancer, Endometrial Neoplasms, Female Urogenital Diseases, +10 more
Locations: Broward Health Medical Center Fort Lauderdale, Florida, United States

Miami Cancer Institute Miami, Florida, United States

Mount Sinai Medical Center Miami Beach, Florida, United States

Parkview Research Center Fort Wayne, Indiana, United States

View all 75 locations

View Trial Details

Recruiting

A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)

NCT06952504

Conditions: Endometrial Cancer, Endometrial Neoplasms, Female Urogenital Diseases, +11 more
Locations: University of South Alabama, Mitchell Cancer Institute ( Site 6033) Mobile, Alabama, United States

Alaska Women's Cancer Care ( Site 6036) Anchorage, Alaska, United States

CHAO Family Comprehensive Cancer Center and Ambulatory Care ( Site 5014) Irvine, California, United States

University of California, Irvine (UCI) Health - UC Irvine Medical Center ( Site 6020) Orange, California, United States

View all 261 locations

View Trial Details

Recruiting

Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma

NCT05112601

Conditions: Adenocarcinoma, Adnexal Diseases, Carcinoma, +28 more
Locations: University of Alabama at Birmingham Cancer Center Birmingham, Alabama, United States

University Cancer and Blood Center LLC Athens, Georgia, United States

Augusta University Medical Center Augusta, Georgia, United States

Saint Alphonsus Cancer Care Center-Boise Boise, Idaho, United States

View all 137 locations

View Trial Details

Recruiting

Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors

NCT06974110

Conditions: Advanced Solid Tumor, Colonic Diseases, Colorectal Cancer, +31 more
Locations: Investigative Site #132 Phoenix, Arizona, United States

Investigative Site #101 San Diego, California, United States

Investigative Site #128 Tampa, Florida, United States

Investigative Site #120 Detroit, Michigan, United States

View all 15 locations

View Trial Details

Recruiting

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

NCT05564377

Conditions: Adnexal Diseases, Advanced Malignant Solid Neoplasm, Anatomic Stage III Breast Cancer AJCC v8, +36 more
Locations: University of Alabama at Birmingham Cancer Center Birmingham, Alabama, United States

University of South Alabama Mitchell Cancer Institute Mobile, Alabama, United States

Alaska Women's Cancer Care Anchorage, Alaska, United States

CTCA at Western Regional Medical Center Goodyear, Arizona, United States

View all 483 locations

View Trial Details

Recruiting

FOG-001 in Locally Advanced or Metastatic Solid Tumors

NCT05919264

Conditions: Adamantinomatous Craniopharyngioma, Adenocarcinoma, Adenoma, +65 more
Locations: Mayo Clinic Phoenix, Arizona, United States

Honor Health Scottsdale, Arizona, United States

Arizona Cancer Center at University of Arizona Tucson, Arizona, United States

University of California, Los Angeles (UCLA) Los Angeles, California, United States

View all 33 locations

View Trial Details

Recruiting

Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors

NCT05797168

Conditions: Adenocarcinoma, Adenocarcinoma of Lung, Adnexal Diseases, +27 more
Locations: Research Site Duarte, California, United States

Research Site Irvine, California, United States

Research Site La Jolla, California, United States

Research Site Aurora, Colorado, United States

View all 60 locations

View Trial Details

Endometrial Neoplasms

Endometrial Neoplasms trial results

Related conditions